BioFocus and CHDI Foundation Enter new Five-Year Collaboration for Huntington’s Disease Therapeutics
News Apr 30, 2010
BioFocus and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington’s disease, announced a new five-year collaboration focused on discovering novel drugs for Huntington’s disease. BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration.
BioFocus will apply its full range of integrated drug discovery services for this program. Integrated biology and chemistry capabilities will be supported by BioFocus’ expertise in complex primary neuronal assay development, high-content screening, fragment-based screening, computational chemistry, ADME/PK and protein crystallography. The new agreement continues and expands the collaboration started in August 2005.
“Having collaborated with CHDI since 2005 in therapeutic target discovery, we are eager to continue working together to develop novel therapies for Huntington's disease and meet this urgent medical need,” said Onno van de Stolpe, CEO of Galapagos. “We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five.”
“BioFocus has delivered expert technologies and experienced staff to therapeutic target and drug discovery research in the fight against Huntington’s disease,” said Ignacio Munoz-Sanjuan, Vice-President, Biology at CHDI. “This has encouraged us to extend and expand the collaboration, with the ultimate goal of finding disease-modifying treatments for Huntington’s.”
Artificial intelligence is having a positive impact on drug development and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling.READ MORE